Pharbaco Central Pharmaceutical No1 JSC

Pharbaco Central Pharmaceutical No1 JSC maintains a debt-to-equity ratio of 1.1, indicating a moderate reliance on debt financing, while its current ratio of 0.5 suggests potential liquidity constraints, as current assets fall significantly below current liabilities. The company's free cash flow is negative at -32.68 billion VND, and capital expenditures of -91.81 billion VND reflect ongoing investment in operations. The company's profitability metrics show a return on equity (ROE) of 2.44% and a return on assets (ROA) of 1.01%, both below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. These figures suggest that Pharbaco is underperforming relative to industry norms in terms of capital efficiency and asset utilization. Pharbaco's revenue is primarily concentrated in Vietnam, with a significant portion derived from domestic hospital sales. Export markets contribute to its revenue, but the extent of geographic diversification is not disclosed. The company does not provide segment-specific revenue breakdowns, limiting visibility into the performance of its various therapeutic product lines. The company's growth trajectory is constrained by its negative free cash flow and high capital expenditures. While revenue for the latest period is reported at 1.08 trillion VND, there is no indication of year-over-year growth or future revenue expansion. The absence of a clear growth strategy or market expansion plans is a concern for long-term investors. Pharbaco faces medium liquidity risk due to its current ratio of 0.5 and negative free cash flow. The risk assessment also notes that net cash is negative after subtracting total debt, signaling potential challenges in meeting short-term obligations. The company's dilution risk is currently low, but the presence of long-term debt at 1.43 trillion VND raises concerns about future refinancing and potential equity dilution. Recent filings and transcripts do not provide specific details on strategic initiatives or operational changes. The company's financial disclosures are limited to standard reporting, with no notable events or announcements that would suggest a shift in business strategy or market positioning.